Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02595866
Title Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Hodgkin's lymphoma

Kaposi's sarcoma

non-Hodgkin lymphoma

hepatocellular carcinoma

Advanced Solid Tumor

melanoma

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.